ALLO
Allogene Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website allogene.com
- Employees(FY) 359
- ISIN US0197701065
Performance
-3.15%
1W
-20.86%
1M
-42.17%
3M
-1.42%
6M
-13.71%
YTD
-54.74%
1Y
Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Investment Analysis Report: ALLO
Overview:
ALLO is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $806,045,201. In this report, we will conduct a comprehensive analysis of ALLO's financial health, valuation, earnings and revenue growth, profitability, op...
Technical Analysis of ALLO 2024-05-10
Overview:
In analyzing the technical indicators for ALLO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-16 08:13
- 2024-05-14 12:56
- 2024-05-14 09:14
- 2024-05-14 03:06
- 2024-05-14 00:56
- 2024-05-13 20:21
- 2024-05-13 17:36
Allogene Therapeutics Prices $110 Million Offering(MT Newswires)
- 2024-05-13 17:10
- 2024-05-13 16:47
- 2024-05-13 16:17
Allogene Therapeutics: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-13 16:14
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines(MT Newswires)
- 2024-05-13 16:01
- 2024-05-13 08:55
- 2024-05-13 05:10
- 2024-05-13 04:47
- 2024-05-13 04:01
- 2024-05-10 09:51
- 2024-05-06 08:30
- 2024-05-05 20:30
- 2024-04-26 10:32
- 2024-04-26 08:30
- 2024-04-25 20:30
- 2024-04-25 10:02
- 2024-04-24 10:01
- 2024-04-23 22:01
- 2024-04-11 14:45
3 Meme Stocks to Sell and Replace With Meme Coins(InvestorPlace)
- 2024-04-09 08:30
- 2024-04-08 20:30
- 2024-04-08 08:46
- 2024-04-07 20:46
Page 1 of 6
previousnext